Last C$0.45 CAD
Change Today -0.03 / -6.25%
Volume 31.3K
RVX On Other Exchanges
Symbol
Exchange
Berlin
Toronto
OTC US
As of 12:18 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

resverlogix corp (RVX) Snapshot

Open
C$0.46
Previous Close
C$0.48
Day High
C$0.47
Day Low
C$0.45
52 Week High
01/30/14 - C$0.89
52 Week Low
12/11/14 - C$0.41
Market Cap
38.4M
Average Volume 10 Days
45.6K
EPS TTM
C$0.24
Shares Outstanding
85.4M
EX-Date
--
P/E TM
1.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for RESVERLOGIX CORP (RVX)

Related News

No related news articles were found.

resverlogix corp (RVX) Related Businessweek News

No Related Businessweek News Found

resverlogix corp (RVX) Details

Resverlogix Corp., a clinical stage biotechnology company, develops small molecules that selectively inhibit Bromodomain and ExtraTerminal domain proteins for high risk vascular diseases. The company is developing RVX-208, a small molecule that is in clinical trials for the treatment of atherosclerosis and other chronic diseases, such as diabetes mellitus and Alzheimer's disease. Resverlogix Corp. is headquartered in Calgary, Canada.

19 Employees
Last Reported Date: 07/29/14

resverlogix corp (RVX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$404.6K
Chief Financial Officer
Total Annual Compensation: C$241.7K
Senior Vice President of Medical Affairs
Total Annual Compensation: C$183.8K
Compensation as of Fiscal Year 2014.

resverlogix corp (RVX) Key Developments

Resverlogix Corp. Presents at LD Micro Conference, Dec-02-2014 04:00 PM

Resverlogix Corp. Presents at LD Micro Conference, Dec-02-2014 04:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States.

Resverlogix Corp. Appoints Michael T. Sweeney, M.D., as Senior Vice President of Clinical Development

Resverlogix Corp. announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development. Dr. Sweeney will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications. This will include the company's Phase 2/3 trial of RVX-208 in patients with high-risk CVD with low HDL and diabetes mellitus.

Resverlogix Corp. - Special Call

Resverlogix Corp. - Special Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVX:CN C$0.45 CAD -0.03

RVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVX.
View Industry Companies
 

Industry Analysis

RVX

Industry Average

Valuation RVX Industry Range
Price/Earnings 1.5x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 1.6x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESVERLOGIX CORP, please visit www.resverlogix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.